Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment

A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin–angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an acute myocardial infarction.1 However, the effectiveness of an agent in patients with chronic heart failure does not necessarily imply that the agent will be effective in patients who have had an acute myocardial infarction. For example, despite the effectiveness of sacubitril–valsartan in decreasing the risk of death from cardiovascular causes or hospitalization . . .